{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:10:03Z","timestamp":1749661803340,"version":"3.41.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1093\/jac\/dkw427","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T15:10:17Z","timestamp":1476803417000},"page":"417-420","source":"Crossref","is-referenced-by-count":4,"title":["<i>In vitro<\/i>evaluation of the effect of linezolid and levofloxacin on<i>Bacillus anthracis<\/i>toxin production, spore formation and cell growth"],"prefix":"10.1093","volume":"72","author":[{"given":"Breanne M.","family":"Head","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Alfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Sitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne F. A.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"2017012307351438000_72.2.417.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"2017012307351438000_72.2.417.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.1995.tb02340.x"},{"key":"2017012307351438000_72.2.417.3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2362-2365.2003"},{"key":"2017012307351438000_72.2.417.4","unstructured":"Ortho-McNeil-Janssen Pharmaceuticals. Levaquin Full Prescribing Information 2008 . http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021721s020_020635s57_020634s52_lbl.pdf ."},{"key":"2017012307351438000_72.2.417.5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00667-09"},{"key":"2017012307351438000_72.2.417.6","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2017012307351438000_72.2.417.7","first-page":"13","article-title":"Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system","volume":"56","author":"Louie","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2017012307351438000_72.2.417.8","unstructured":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Ninth Edition: Approved Standard M07-A9 . CLSI, Wayne, PA, USA, 2012."},{"key":"2017012307351438000_72.2.417.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00497-10"},{"key":"2017012307351438000_72.2.417.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.5.427"},{"key":"2017012307351438000_72.2.417.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.09.002"},{"key":"2017012307351438000_72.2.417.12","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02336-09"},{"key":"2017012307351438000_72.2.417.13","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01862-12"},{"key":"2017012307351438000_72.2.417.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01109-10"},{"key":"2017012307351438000_72.2.417.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2013.04.003"},{"key":"2017012307351438000_72.2.417.16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr033"},{"key":"2017012307351438000_72.2.417.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01830-13"},{"key":"2017012307351438000_72.2.417.18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6997(25)07327-2","article-title":"Antibiotic synergism and antagonism: an assessment of the problem","volume":"5","author":"Jawetz","year":"1953","journal-title":"Pharmacol Rev"},{"key":"2017012307351438000_72.2.417.19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg364"},{"key":"2017012307351438000_72.2.417.20","unstructured":"Pharmacia and Upjohn. Zyvox . Pfizer Inc., New York, NY, USA, 2005. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4254b_02_05_KP%20LinezolidFDAlabel52005.pdf ."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/2\/417\/9684028\/dkw427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T16:36:09Z","timestamp":1749659769000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,23]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1093\/jac\/dkw427"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw427","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}